January 29, 2018

Therapeutic Vaccine Combination May Help Patients With Myelodysplastic Syndrome

 It may be possible to vaccinate against induced NY-ESO-1 expression to produce an antigen-specific immune response in patients with high-risk myelodysplastic syndrome (MDS), according to a […]
January 26, 2018

Venetoclax Active in CLL Progressing After Idelalisib

Venetoclax had promising clinical activity, with a high objective response rate among patients with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with idelalisib, according […]
January 23, 2018

Engineered Tumor-Specific T Cells May Help Relapsed Hodgkin Lymphoma Patients

 It may be possible to treat patients with relapsed Hodgkin lymphoma (HL) with a new engineered T-cell approach that is less toxic and does not require […]
January 23, 2018

Nivolumab Plus Ipilimumab Offers Improved Survival Outcomes in Certain Metastatic CRC Patients

The combination of nivolumab and ipilimumab yielded high response rates and encouraging survival outcomes in a cohort of previously treated patients with DNA mismatch repair-deficient (dMMR)/microsatellite […]
January 18, 2018

MHOA Selected as a Recipient of the COLA Laboratory Excellence Award

This award signifies MHOA’S laboratory’s commitment to performing quality patient testing and overall laboratory practices. The Laboratory Excellence Award is achieved by those laboratories that are […]
January 1, 2018

New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study

Phase 3 results from the ECHELON-1 study, presented at the 59th Annual Meeting & Exposition of the American Society of Hematology, showed superior modified progression-free survival […]
December 19, 2017

Copanlisib May Benefit Patients with Relapsed or Refractory Indolent B-cell Lymphoma

Updated analyses are validating the efficacy of copanlisib in the treatment of relapsed or refractory indolent B-cell lymphoma. Investigators reported at the 2017 annual meeting of […]
December 15, 2017

FDA approves first treatment for breast cancer with inherited genetic mutation

The U.S. Food and Drug Administration today expanded the approved use of Lynparza (olaparib tablets) to include the treatment of patients with certain types of breast […]
December 12, 2017

Mogamulizumab May Benefit Patients with Cutaneous T-Cell Lymphoma

Clinicians may soon have a valuable new therapeutic option for treating patients with cutaneous T-cell lymphoma (CTCL). Results of a randomized phase III study presented at […]
December 11, 2017

Selinexor Plus Sorafenib May Benefit Patients with Relapsed/Refractory FLT3-Mutated AML

The combination of selinexor and sorafenib appears to be safe with clinical activity and apoptosis induction in patients with relapsed and/or refractory FLT3-mutated acute myeloid leukemia […]
December 5, 2017

New Drug Target Discovered for Acute Myeloid Leukemia

 A new study has found that inhibiting the METTL3 gene destroys human and mouse acute myeloid leukemia (AML) cells without harming non-leukemic blood cells 
November 13, 2017

Responses Better With Bosutinib vs Imatinib in Untreated CML

Treatment with first-line bosutinib resulted in improved outcomes for patients with chronic-phase chronic myeloid leukemia (CML) compared with treatment with imatinib, according to results of the […]
November 9, 2017

Alectinib Approved as First-Line Therapy for ALK-Positive Metastatic NSCLC

Clinicians now have a new first-line therapy that may significantly improve care for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC). On […]
September 13, 2017

AML FDA Breaks New Ground With First Approved Gene Therapy For Cancer

When oncologist Dr. Carl June heard the Food and Drug Administration’s decision to bring the first gene therapy to market in the US, he pinched himself, […]
August 18, 2017

FDA Approves New Acute Lymphoblastic Leukemia Treatment

The US Food and Drug Administration (FDA) has approved inotuzumab ozogamicin (Besponsa) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in […]
July 6, 2017

Nivolumab Offers Durable Responses in Relapsed/Refractory Hodgkin Lymphoma

Nivolumab was associated with durable objective response rates (ORRs) in adults with relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplantation (ASCT), according to […]
June 28, 2017

Experimental FLT3 Inhibitor May Benefit Patients with Refractory AML

Clinicians may soon have a new tool to aid patients with refractory acute myeloid leukemia (AML). Researchers at the Perelman School of Medicine at the University […]
June 20, 2016

ASCO 2016

The American Society of Clinical Oncology’s annual meeting, one of the most important cancer conferences of the year, concluded June 7th. This year’s theme was ‘collective […]
February 5, 2016

ASH 2015

The American Society of Hematology (ASH), the premier event for scientific exchange in the field of hematology, recently concluded its annual meeting in Orlando, Florida. Oral […]
July 7, 2015

News From ASCO 2015

The annual American Society of Clinical Oncology (ASCO) meeting was held last week in Chicago, bringing together thousands of oncology professionals from around the world to […]
August 1, 2014

MHOA Research and Clinical Trials

[mc_carousel id=”carousel” carousel_images=”2770,2771,2772,2750,2773″ features_images_loop=”1″ lightbox_icon_color=”blue_light” autoplay=”0″ pause_on_hover=”1″ scroll=”1″ effect=”scroll” easing=”swing” duration=”500″ top_margin=”page_margin_top_section” el_position=”first last”] Thank You For Your Interest In Clinical Trials at MHOA Currently Enrolling […]